期刊文献+

新型铂类抗癌药舒尼铂原料药中催化剂钯残留量的测定

Determination of Residual Catalyst Palladium in Shuniplatin Crude Product by ICP-MS
下载PDF
导出
摘要 采用封闭体系微波消解法,电感耦合等离子体质谱法测定了舒尼铂原料药中催化剂钯的残留量,并进行方法学验证。实验结果表明钯质量浓度在0.01~150μg·L-1的范围内,与钯强度和内标铟强度的比值呈良好的线性关系,重复性试验的RSD为2.40%,加标回收率为96.79%~112.98%,检测限为0.0025μg·g-1,定量限为0.0084μg·g-1;三批样品测定结果分别为2.21、3.61、1.78μg·g-1。本方法便捷、准确、精度高,可满足舒尼铂原料药中催化剂钯残留量测定的要求。 A method to determine the residual catalyst palladium in Shuniplatin was developed and applied to the study of quality control.The samples were digested by closed-vessel microwave system and analyzed by ICP-MS.The linear relationship was good in concentration range 0.1~150μg·L-1,the relative standard deviation of repeatability was 2.2%,the recoveries of palladium were 96.79%~112.98%,the limit of detection was 0.0025μg·g-1,and the limit of quantitation was 0.0084μg·g-1.The results of residual catalyst palladium in three samples were 2.21,3.61 and 1.78μg·g-1.The ICP-MS method is sensitive and accurate,feasible for palladium determination in Shuniplatin.
作者 张晓南 普冰清 陈雪江 李东娴 牛延菲 徐红贵 ZHANG Xiao-nan;PU Bing-qing;CHEN Xue-jiang;LI Dong-xian;NIU Yan-fei;XU Hong-gui(Yunnan Institute of Materia Medica,Yunnan Kunming 650111;Yunnan Bai Yao Group Innovation and R&D Center,Yunnan Kunming 650111;Yunnan Province Company Key Laboratory for TCM and Ethnic Drug of New Drug Creation,Yunnan Kunming 650111,China)
出处 《广州化工》 CAS 2020年第16期83-84,159,共3页 GuangZhou Chemical Industry
关键词 舒尼铂 铂类抗癌药 钯残留量 微波消解-电感耦合等离子体质谱法(ICP-MS) Shuniplatin platinum drugs palladium residue ICP-MS
  • 相关文献

参考文献3

二级参考文献150

  • 1R B Weiss, M C Christian. Drugs, 1993, 46(3) : 360-377.
  • 2J Reedijk. Chem. Commun. , 1996, (7): 801 -806.
  • 3M Galanski, V B Arion, M A Jakupee et al. Curr. Pharma. Design, 2003, 9(25) : 2078 -2089.
  • 4M Galanski, M A Jakupec, B K Keppler. Curr. Med. Chem. , 2005, 12(18) : 2075 -2094.
  • 5D Lebwohl, R Canetta. Eur. J. Cancer, 1998, 34(10): 1522 -1534.
  • 6R J Knox, F Ffiedlos, D A Lydall et al. Cancer Res. , 1986, 46(4) : 1972 -1979.
  • 7J M Woynarowski, S Faivre, M C S Herzig et al. Mol. Pharmacol. , 2000, 58(5) : 920 -927.
  • 8D Wang, S J Lippard. Nat. Rev. Drug Disc. , 2005, 4(4) : 307 -320.
  • 9M H Baik, R A Friesner, S J Lippard. J. Am. Chem. Soe. , 2003, 125(46) : 14082- 14092.
  • 10M E Bosch, A J R Sanchez, F S Rojas et al. J. Pharma. Biomed. Anal. , 2008, 47(3) : 451 -459.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部